Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity
2008 ◽
Vol 14
(1)
◽
pp. 169-177
◽
Keyword(s):
Phase I
◽
2008 ◽
Vol 15
(6)
◽
pp. 133S
Keyword(s):
1989 ◽
Vol 43
(1)
◽
pp. 41-44
◽
Keyword(s):
2006 ◽
Vol 87
(5)
◽
pp. 1181-1188
◽
2019 ◽
Vol 153
(4)
◽
pp. 502-512
◽
Keyword(s):
2021 ◽
Vol 118
(41)
◽
pp. e2108359118
Keyword(s):
2020 ◽
Vol 108
(3)
◽
pp. e454-e455
Keyword(s):
Keyword(s):
2011 ◽
Vol 2011
◽
pp. 1-6
◽